SPOTLIGHT: Nymox shares hit by panel rejection

Shares of Nymox Pharmaceuticals took a beating after the company announced that an FDA panel had rejected its kit for detecting Alzheimer's. By a 5-2 vote the panel asked for more data on verification and clarification of test results. CEO Paul Averback said in a statement that he was anticipating working with the FDA on gaining more data. Report

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.